Ron Schaafsma

A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma

Henk M. Lokhorst, Bronno van der Holt, Sonja Zweegman et al. · Blood · 2009 · 275 citations · Full text

Medicine, Hematology, Oncology +17

Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients

Francesca Gay, Alessandra Larocca, Pierre W. Wijermans et al. · Blood · 2011 · 268 citations · Full text

Medicine, Oncology, Chemotherapy +8

Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

Hartmut Goldschmidt, H M Lokhorst, E K et al. · Leukemia · 2017 · 201 citations · Full text

Medicine, Hematology, Oncology +14

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

Bob Löwenberg, Joachim Beck, Carlos Graux et al. · Blood · 2010 · 144 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +4

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma

H M Lokhorst, Ingo GH Schmidt-Wolf, Pieter Sonneveld et al. · Haematologica · 2007 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14